pertussis

Pertussis
Classification and external resources
A young boy coughing due to pertussis.
ICD-10	A37
ICD-9	033
DiseasesDB	1523
MedlinePlus	001561
eMedicine	emerg/394 ped/1778
MeSH	D01491

Pertussis, also known as whooping cough ( /ˈhuːpɪŋ kɒf/ or /ˈhwuːpɪŋ kɒf/), is a highly contagious bacterial disease caused by Bordetella pertussis. In some countries, this disease is called the 100 days' cough or cough of 100 days.^[1]

Symptoms are initially mild, and then develop into severe coughing fits, which produce the namesake high-pitched "whoop" sound in infected babies and children when they inhale air after coughing.^[2] The coughing stage lasts for approximately six weeks before subsiding.

Prevention via vaccination is of primary importance as treatment is of little clinical benefit to the person infected.^[3] Antibiotics, however, do decrease the duration of infectiousness and are thus recommended.^[3] It is estimated that the disease currently affects 48.5 million people yearly, resulting in nearly 295,000 deaths.^[4]

Signs and symptoms

The classic signs of pertussis are a paroxysmal cough, inspiratory whoop, and vomiting after coughing.^[5] The cough from pertussis has been documented to cause subconjunctival hemorrhages, rib fractures, urinary incontinence, hernias, post-cough fainting, and vertebral artery dissection.^[5] If there is vomiting after a coughing spell or an inspiratory whooping sound on coughing, the likelihood that the illness is pertussis is nearly doubled. On the other hand, the absence of a paroxysmal cough or posttussive emesis makes it almost half as likely.^[5]

The incubation period is typically seven to ten days in infants or young children, after which there are usually mild respiratory symptoms, mild coughing, sneezing, or runny nose. This is known as the catarrhal stage. After one to two weeks, the coughing classically develops into uncontrollable fits, each with five to ten forceful coughs, followed by a high-pitched "whoop" sound in younger children, or a gasping sound in older children, as the patient struggles to breathe in afterwards (paroxysmal stage). Fits can occur on their own or can be triggered by yawning, stretching, laughing, eating or yelling; they usually occur in groups, with multiple episodes every hour around the clock. This stage usually lasts two to eight weeks, or sometimes longer. A gradual transition then occurs to the convalescent stage, which usually lasts one to two weeks. This stage is marked by a decrease in paroxysms of coughing, both in frequency and severity, and a cessation of vomiting.

Diagnosis

Methods used in laboratory diagnosis include culturing of nasopharyngeal swabs on Bordet-Gengou medium, polymerase chain reaction (PCR), direct immunofluorescence (DFA), and serological methods. The bacteria can be recovered from the patient only during the first three weeks of illness, rendering culturing and DFA useless after this period, although PCR may have some limited usefulness for an additional three weeks. For most adults and adolescents, who often do not seek medical care until several weeks into their illness, serology may be used to determine whether antibody against pertussis toxin or another component of B. pertussis is present at high levels in the blood of the patient. By this stage they have been contagious for some weeks and may have spread the infection to many people. Because of this, adults, who are not in great danger from pertussis, are increasingly being encouraged to be vaccinated.

A similar, milder disease is caused by B. parapertussis.^[6]

Prevention

The primary method of prevention for pertussis is vaccination. There is insufficient evidence to determine the effectiveness of antibiotics in those who have been exposed but are without symptoms.^[7] Prophylactic antibiotics, however, are still frequently used in those who have been exposed and are at high risk of severe disease (such as infants).^[3]

Vaccine

Pertussis vaccines are effective,^[8] routinely recommended by the World Health Organization ^[9] and the Center for Disease Control and Prevention,^[10] and saved over half a million lives in 2002.^[10] The multi-component acellular pertussis vaccine, for example, is between 71-85% effective with greater effectiveness for more severe disease.^[8]

The duration of protection is between five to ten years. This covers childhood, which is the time of greatest exposure and greatest risk of death from pertussis.^[5][11] For children, the immunizations are commonly given in combination with immunizations against tetanus, diphtheria, polio and haemophilus influenzae type B, at ages two, four, six, and 15–18 months. A single later booster is given at four to six years of age.

A 2011 study by the CDC indicated that the duration of protection may only last three to six years. Dr. Paul Offit, chief of the Director of the Vaccine Education Center at the Children's Hospital of Philadelphia, comments that the last pertussis vaccination people receive may be their booster at age 11 or 12 years old. However, he states that it is important for adults to have immunity as well, to prevent transmission of the disease to infants.^[12]

The pertussis component of the DPT vaccine accounted for most of the minor local and systemic side effects in many vaccinated infants (such as mild fever or soreness at the injection site).

Immunization against pertussis does not confer life-long immunity. While adults rarely die if they contract pertussis after the effects of their childhood vaccinations have worn off, they may transmit the disease to people at much higher risk of death. To reduce morbidity and spread of the disease, Canada, France, the U.S. and Germany have approved booster shots. The booster for adults is combined with the tetanus vaccine, abbreviated TDaP for Tetanus Diptheria and Pertussis, similar to the childhood vaccine called the DTaP (Diptheria Tetanus and Pertussis). Adults must request the TDaP instead of a tetanus shot in order to receive the multi-vaccine.

Infection with pertussis induces temporary natural immunity, but like the vaccine does not confer a lasting protective immunity.^[13]

The newer acellular vaccine, known as DTaP, has greatly reduced the incidence of adverse effects compared to the earlier "whole-cell" pertussis vaccine.^[14]

Management

The treatment of pertussis is generally ineffective at changing clinical outcomes; thus, prevention is of primary importance.^[3] Antibiotics do, however, decrease the duration of infectiousness and thus prevent spread.^[3] The antibiotic erythromycin is currently the first line treatment.^[7] Newer macrolides are frequently recommended due to lower rates of side effects.^[3] Trimethoprim-sulfamethoxazole may be used in those with allergies to first line agents or in infants who have a risk of pyloric stenosis from macrolides.^[3] Effective treatments of the cough associated with this condition have not yet been developed.^[15]

Prognosis

Common complications of the disease include pneumonia, encephalopathy, earache, or seizures.

Most healthy older children and adults will have a full recovery from pertussis, however those with comorbid conditions can have a higher risk of morbidity and mortality.

Infection in newborns is particularly severe. Pertussis is fatal in an estimated one in 100 infants under two months, and fatal in one in 200 infants aged two to 12 months. Infants under one are also more likely to develop complications (e.g., pneumonia (20%), encephalopathy, seizures (1%), failure to thrive, and death (0.2%)). Pertussis can cause severe paroxysm-induced cerebral hypoxia and apnea. Reported fatalities from pertussis in infants have increased substantially over the past 20 years.^[16]

Epidemiology

Disability-adjusted life year for pertussis per 100,000 inhabitants.

  no data

  ≤ 25

  25-50

  50-75

  75-100

  100-150

  150-200

  200-300

  300-400

  400-500

  500-600

  600-700

  ≥ 700

Worldwide whooping cough affects 48.5 million people yearly resulting in nearly 295,000 deaths.^[4] This is despite generally high coverage with the DTP and DTaP vaccines, pertussis is one of the leading causes of vaccine-preventable deaths world-wide.^{[citation needed]} 90% of all cases occur in developing countries.^{[citation needed]}

Before vaccines, an average of 157 cases per 100,000 persons were reported in the U.S., with peaks reported every two to five years; more than 93% of reported cases occurred in children under 10 years of age. The actual incidence was likely much higher. After vaccinations were introduced in the 1940s, incidence fell dramatically to less than 1 per 100,000 by 1970. Incidence rates have increased somewhat since 1980.

Pertussis is the only vaccine-preventable disease that is associated with increasing deaths in the U.S. The number of deaths increased from four in 1996 to 17 in 2001, almost all of which were infants under one year.^[17] In Canada, the number of pertussis infections has varied between 2,000 to 10,000 reported cases each year over the last ten years.^[18] Australia reports an average of 10,000 cases a year, but the number of cases has increased in recent years.^[19] In 2010 ten infants in California died and health authorities declared an epidemic.^[20][21] Doctors had been misdiagnosing the infants' condition despite having seen infants on multiple visits.^[22] In the U.S. pertussis in adults has increased significantly since about 2004.^[23]

History

B. pertussis was isolated in pure culture in 1906 by Jules Bordet and Octave Gengou, who also developed the first serology and vaccine. The complete B. pertussis genome of 4,086,186 base pairs was sequenced in 2004.^[24]

Efforts to develop an inactivated whole-cell pertussis vaccine began soon after B. pertussis was grown in pure culture in 1906. In the 1920s, Dr. Louis W. Sauer developed a vaccine for whooping cough at Evanston Hospital (Evanston, IL). In 1925, the Danish physician Thorvald Madsen was the first to test a whole-cell pertussis vaccine on a wide scale.^[25] He used the vaccine to control outbreaks in the Faroe Islands in the North Sea. In 1942, the American scientist Pearl Kendrick combined the whole-cell pertussis vaccine with diphtheria and tetanus toxoids to generate the first DTP combination vaccine. To minimize the frequent side effects caused by the pertussis component of the vaccine, the Japanese scientist Yuji Sato developed an acellular pertussis vaccine consisting of purified haemagglutinins (HAs: filamentous strep throat and leucocytosis-promoting-factor HA), which are secreted by B. pertussis into the culture medium. Sato's acellular pertussis vaccine was used in Japan since 1981.^[26] Later versions of the acellular pertussis vaccine used in other countries consisted of additional defined components of B. pertussis and were often part of the DTaP combination vaccine.

Society and culture

Much of the controversy surrounding the DPT vaccine in the 1970s and 1980s related to the question of whether the whole-cell pertussis component caused permanent brain injury in rare cases, called pertussis vaccine encephalopathy. Despite this possibility, doctors recommended the vaccine due to the overwhelming public health benefit, because the claimed rate was very low (one case per 310,000 immunizations, or about 50 cases out of the 15 million immunizations each year in the United States), and the risk of death from the disease was high (pertussis killed thousands of Americans each year before the vaccine was introduced).^[27]

No studies showed a causal connection, and later studies showed no connection of any type between administration of the DPT vaccine and permanent brain injury. The alleged vaccine-induced brain damage proved to be an unrelated condition, infantile epilepsy.^[28] Eventually evidence against the hypothesized existence of pertussis vaccine encephalopathy mounted to the point that in 1990, the Journal of American Medical Association called it a "myth" and "nonsense".^[29]

However, before that point, criticism of the studies showing no connection and a few well-publicized anecdotal reports of permanent disability that were blamed on the DPT vaccine gave rise to anti-DPT movements in the 1970s.^[30] The negative publicity and fear-mongering caused the immunization rate to fall in several countries, including Great Britain, Sweden, and Japan. In many cases, a dramatic increase in the incidence of pertussis followed.^[31]

Unscientific claims about the vaccine pushed suppliers of the vaccines out of the market.^[27] In the United States, low profit margins and an increase in vaccine-related lawsuits led many manufacturers to stop producing the DPT vaccine by the early 1980s.^[27]

In 1982, the television documentary "DTP: Vaccine Roulette" depicted the lives of children whose severe disabilities were inaccurately blamed on the DPT vaccine by reporter Lea Thompson.^[32] The negative publicity generated by the documentary led to a tremendous increase in the number of lawsuits filed against vaccine manufacturers.^[33] By 1985, manufacturers of vaccines had difficulty obtaining liability insurance. The price of the DPT vaccine skyrocketed, leading to shortages around the country. Only one manufacturer of the DPT vaccine remained in the U.S. by the end of 1985. To avert a vaccine crisis, Congress in 1986 passed the National Childhood Vaccine Injury Act (NCVIA), which established a federal no-fault system to compensate victims of injury caused by mandated vaccines.^[34] The majority of claims that have been filed through the NCVIA have been related to injuries allegedly caused by the whole-cell DPT vaccine.

The concerns about side effects led Yuji Sato to introduce an even safer acellular version of the pertussis vaccine for Japan in 1981. The acellular pertussis vaccine was approved in the United States in 1992 for use in the combination DTaP vaccine. Research has shown the acellular vaccine to be safer, with fewer reports of adverse effects.^[35]

References

External links

Wikimedia Commons has media related to: Pertussis

• Pertussis at Todar's Online Textbook of Bacteriology

Related information